Antileukemic Effect of Graft-versus-Host Disease in Human Recipients of Allogeneic-Marrow Grafts, New England Journal of Medicine, vol.300, issue.19, pp.1068-1073, 1979. ,
DOI : 10.1056/NEJM197905103001902
Optimising the conditioning regimen for acute myeloid leukaemia, Best Practice & Research Clinical Haematology, vol.22, issue.4, pp.543-550, 2009. ,
DOI : 10.1016/j.beha.2009.10.004
URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3207636/pdf
Age and acute myeloid leukemia, Blood, vol.107, issue.9, pp.3481-3485, 2006. ,
DOI : 10.1182/blood-2005-09-3724
Extramedullary leukemia in children with acute myeloid leukemia: A population-based cohort study from the Nordic Society of Pediatric Hematology and Oncology (NOPHO) Pediatr Blood Cancer, 2017. ,
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet, Blood, vol.115, issue.3, pp.453-474, 2010. ,
DOI : 10.1182/blood-2009-07-235358
Is secondary leukemia an independent poor prognostic factor in acute myeloid leukemia?, Best Practice & Research Clinical Haematology, vol.20, issue.1, pp.29-37, 2007. ,
DOI : 10.1016/j.beha.2006.10.006
The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials, Blood, vol.98, issue.6, pp.1752-1759, 2001. ,
DOI : 10.1182/blood.V98.6.1752
Potent Graft-versus-Leukemia Effect after Reduced-Intensity Allogeneic SCT for Intermediate-Risk AML with FLT3-ITD or Wild-Type NPM1 and CEBPA without FLT3-ITD, Biology of Blood and Marrow Transplantation, vol.18, issue.12, pp.1845-1850, 2012. ,
DOI : 10.1016/j.bbmt.2012.06.012
Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations, Blood. Blood, vol.124106, issue.1012, pp.3441-34493740, 2005. ,
but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome, Blood, vol.113, issue.13, pp.3088-3091, 2009. ,
Risk factors for relapse after allogeneic transplantation in acute myeloid leukemia, Haematologica, vol.101, issue.1, pp.20-25, 2016. ,
DOI : 10.3324/haematol.2015.139105
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel, Blood, vol.129, issue.4, pp.424-447, 2017. ,
DOI : 10.1182/blood-2016-08-733196
Prognostic impact of day 15 blast clearance in risk-adapted remission induction chemotherapy for younger patients with acute myeloid leukemia: long-term results of the multicenter prospective LAM-2001 trial by the GOELAMS study group, Haematologica, vol.99, issue.1, pp.46-53, 2014. ,
DOI : 10.3324/haematol.2013.091819
URL : https://hal.archives-ouvertes.fr/hal-00854975
ABCG2, Cytogenetics, and Age Predict Relapse after Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in Complete Remission, Biology of Blood and Marrow Transplantation, vol.22, issue.9, pp.1621-1626, 2016. ,
DOI : 10.1016/j.bbmt.2016.05.002
Impact of FLT3 Internal Tandem Duplication on the Outcome of Related and Unrelated Hematopoietic Transplantation for Adult Acute Myeloid Leukemia in First Remission: A Retrospective Analysis, Journal of Clinical Oncology, vol.30, issue.7, pp.735-741, 2012. ,
DOI : 10.1200/JCO.2011.36.9868
FLT3-ITD with DNMT3A R882 double mutation is a poor prognostic factor in Chinese patients with acute myeloid leukemia after chemotherapy or allogeneic hematopoietic stem cell transplantation, International Journal of Hematology, vol.27, issue.5, 2017. ,
DOI : 10.1038/leu.2012.317
Analysis of prognosis in acute myeloid leukemia treated with allogeneic hematopoietic stem cell transplantation], Zhongguo Shi Yan Xue Ye Xue Za Zhi, vol.23, issue.1, pp.173-177, 2015. ,
NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on the Epidemiology and Natural History of Relapse following Allogeneic Cell Transplantation, Biology of Blood and Marrow Transplantation, vol.16, issue.7, pp.871-890, 2010. ,
DOI : 10.1016/j.bbmt.2010.04.004
Outcomes of Allogeneic Hematopoietic Cell Transplantation for Adolescent and Young Adults Compared with Children and Older Adults with Acute Myeloid Leukemia, Biology of Blood and Marrow Transplantation, vol.18, issue.6, pp.861-873, 2012. ,
DOI : 10.1016/j.bbmt.2011.10.031
Factors predicting outcome after allogeneic transplant in refractory acute myeloid leukemia: a retrospective analysis of Gruppo Italiano Trapianto di Midollo Osseo (GITMO), Bone Marrow Transplantation, vol.15, issue.7, pp.955-961, 2017. ,
DOI : 10.1016/j.blre.2012.11.001
Allogeneic Hematopoietic Cell Transplantation Outcomes in Acute Myeloid Leukemia: Similar Outcomes Regardless of Donor Type, Biology of Blood and Marrow Transplantation, vol.21, issue.2, pp.357-363, 2015. ,
DOI : 10.1016/j.bbmt.2014.10.030
A disease risk index for patients undergoing allogeneic stem cell transplantation, Blood, vol.120, issue.4, pp.905-913, 2012. ,
DOI : 10.1182/blood-2012-03-418202
Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation, Blood, vol.123, issue.23, pp.3664-3671, 2014. ,
DOI : 10.1182/blood-2014-01-552984
Validating the Allogeneic Stem Cell Transplantation Disease Risk Index, Transplantation, vol.99, issue.1, pp.128-132, 2015. ,
DOI : 10.1097/TP.0000000000000257
Thymic recovery after allogeneic hematopoietic cell transplantation with non-myeloablative conditioning is limited to patients younger than 60 years of age, Haematologica, vol.96, issue.2, pp.298-306, 2011. ,
DOI : 10.3324/haematol.2010.029702
Association between Thymic Function and Allogeneic Hematopoietic Stem Cell Transplantation Outcome: Results of a Pediatric Study, Biology of Blood and Marrow Transplantation, vol.21, issue.6, pp.1099-1105, 2015. ,
DOI : 10.1016/j.bbmt.2015.02.010
Bone marrow or peripheral blood stem cell transplantation from unrelated donors in adult patients with acute myeloid leukaemia, an Acute Leukaemia Working Party analysis in 2262 patients, Journal of Internal Medicine, vol.121, issue.5, pp.472-483, 2012. ,
DOI : 10.1046/j.1365-2141.2003.04364.x
History of consolidation is prognostic in AML patients undergoing allogeneic hematopoietic cell transplantation in minimal residual disease-negative first complete remission Matched unrelated or matched sibling donors result in comparable outcomes after non-myeloablative HSCT in patients with AML or MDS, Am J Hematol. 2017. 30. Robin M Bone Marrow Transplant, vol.48, issue.10, pp.1296-1301, 2013. ,
Improved outcome in relapsed and refractory myeloid malignancies for unrelated vs related donor allogeneic peripheral blood-derived hematopoietic cell transplantation, Bone Marrow Transplantation, vol.90, issue.8, pp.1309-1315, 2010. ,
DOI : 10.1200/JCO.2007.15.5184
High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation, Blood, vol.110, issue.13, pp.4576-4583, 2007. ,
DOI : 10.1182/blood-2007-06-097386
Outcomes after Transplantation of Cord Blood or Bone Marrow from Unrelated Donors in Adults with Leukemia, New England Journal of Medicine, vol.351, issue.22, pp.2265-2275, 2004. ,
DOI : 10.1056/NEJMoa041276
Effect of Graft Source on Unrelated Donor Hemopoietic Stem Cell Transplantation in Adults with Acute Myeloid Leukemia after Reduced-Intensity or Nonmyeloablative Conditioning: A Study from the Soci??t?? Francaise de Greffe de Moelle et de Th??rapie Cellulaire, Biology of Blood and Marrow Transplantation, vol.21, issue.6, pp.1059-1067311310, 2013. ,
DOI : 10.1016/j.bbmt.2015.02.014
Higher rates of relapse in maternal recipients of haploidentical hematopoietic stem cell transplantation from adult offspring donors for AML and myelodysplastic syndrome, Bone Marrow Transplantation, vol.8, issue.10, 2017. ,
DOI : 10.1111/j.1600-6143.2008.02374.x
Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect, Blood, vol.100, issue.6, pp.1935-1947, 2002. ,
DOI : 10.1182/blood-2002-02-0350
Role of natural killer cell alloreactivity in HLAmismatched hematopoietic stem cell transplantation, Blood, vol.94, issue.1, pp.333-339, 1999. ,
Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia, Blood, vol.113, issue.3, pp.726-732, 2009. ,
DOI : 10.1182/blood-2008-07-171926
Missing HLA C group 1 ligand in patients with AML and MDS is associated with reduced risk of relapse and better survival after allogeneic stem cell transplantation with fludarabine and treosulfan reduced toxicity conditioning CMV serostatus still has an important prognostic impact in de novo acute leukemia patients after allogeneic stem cell transplantation: a report from the Acute Leukemia Working Party of EBMT, Am J Hematol. Blood, vol.41122, pp.3359-3364, 2013. ,
Allogeneic blood stem cell and bone marrow transplantation for acute myelogenous leukemia and myelodysplasia: influence of stem cell source on outcome Mobilized peripheral blood stem cells compared with bone marrow from HLA-identical siblings for reduced-intensity conditioning transplantation in acute myeloid leukemia in complete remission: a retrospective analysis from the Acute Leukemia Working Party of EBMT, Bone Marrow Transplant. Eur J Haematol, vol.2489, issue.113, pp.1177-1183206, 1999. ,
Female donors contribute to a selective graft-versus-leukemia effect in male recipients of HLA-matched, related hematopoietic stem cell transplants, Blood, vol.103, issue.1, pp.347-352, 2004. ,
DOI : 10.1182/blood-2003-07-2603
Comparable survival after HLA-well-matched unrelated or matched sibling donor transplantation for acute myeloid leukemia in first remission with unfavorable cytogenetics at diagnosis, Blood, vol.116, issue.11, pp.1839-1848, 2010. ,
DOI : 10.1182/blood-2010-04-278317
Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT), Leukemia, vol.18, issue.12, pp.2304-2312, 2005. ,
DOI : 10.1016/S0140-6736(00)02137-1
Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes, Blood, vol.108, issue.3, pp.836-846, 2006. ,
DOI : 10.1182/blood-2005-11-4503
Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity, Leukemia, vol.19, issue.2, pp.322-328, 2006. ,
DOI : 10.1038/sj.leu.2403771
Comparison of conditioning regimens of various intensities for allogeneic hematopoietic SCT using HLA-identical sibling donors in AML and MDS with <10% BM blasts: a report from EBMT, Bone Marrow Transplantation, vol.118, issue.6, pp.761-770, 2013. ,
DOI : 10.1182/blood-2011-01-332007
Dose-Reduced Versus Standard Conditioning Followed by Allogeneic Stem-Cell Transplantation for Patients With Myelodysplastic Syndrome: A Prospective Randomized Phase III Study of the EBMT (RICMAC Trial), Journal of Clinical Oncology, vol.35, issue.19, pp.2157-2164, 2017. ,
DOI : 10.1200/JCO.2016.70.7349
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes, Journal of Clinical Oncology, vol.35, issue.11, pp.1154-1161, 2017. ,
DOI : 10.1200/JCO.2016.70.7091
Randomized study of 2 reduced-intensity conditioning strategies for human leukocyte antigen-matched, related allogeneic peripheral blood stem cell transplantation, Cancer, vol.47, issue.3, pp.602-611, 2013. ,
DOI : 10.1038/bmt.2012.3
Sequential Intensified Conditioning Regimen Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Intermediate- or High-Risk Acute Myeloid Leukemia in Complete Remission: A Study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation, Biology of Blood and Marrow Transplantation, vol.23, issue.2, pp.278-284, 2017. ,
DOI : 10.1016/j.bbmt.2016.11.002
Sequential regimen of clofarabine, cytosine arabinoside and reduced-intensity conditioned transplantation for primary refractory acute myeloid leukemia, Haematologica, vol.102, issue.1, pp.184-191, 2017. ,
DOI : 10.3324/haematol.2016.150326
URL : https://hal.archives-ouvertes.fr/hal-01471574
Fractionated gemtuzumab ozogamicin combined with intermediate-dose cytarabine and daunorubicin as salvage therapy in very high-risk AML patients: a bridge to reduced intensity conditioning transplant?, Annals of Hematology, vol.101, issue.3, pp.363-371, 2017. ,
DOI : 10.3324/haematol.2016.145763
Sequential chemotherapy followed by reduced-intensity conditioning and allogeneic haematopoietic stem cell transplantation in adult patients with relapse or refractory acute myeloid leukaemia: a survey from the Acute Leukaemia Working Party of EBMT, British Journal of Haematology, vol.18, issue.3, pp.431-439, 2017. ,
DOI : 10.1016/j.bbmt.2012.06.014
Graft-versus-leukemia reactions after bone marrow transplantation, Blood, vol.75, issue.3, pp.555-562, 1990. ,
Impact of T-cell depletion on outcome of allogeneic bone-marrow transplantation for standard-risk leukaemias Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies, Lancet. Blood, vol.2117, issue.5925, pp.175-1786963, 1987. ,
Impact of in vivo T-cell depletion on outcome of AML patients in first CR given peripheral blood stem cells and reduced-intensity conditioning allo-SCT from a HLA-identical sibling donor: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO), Bone Marrow Transplant. Blood, vol.4998, issue.310, pp.389-3962942, 2001. ,
Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial, The Lancet Oncology, vol.17, issue.2, pp.164-173, 2016. ,
DOI : 10.1016/S1470-2045(15)00462-3
Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host Disease, New England Journal of Medicine, vol.374, issue.1, pp.43-53, 2016. ,
DOI : 10.1056/NEJMoa1506002
Early human cytomegalovirus replication after transplantation is associated with a decreased relapse risk: evidence for a putative virus-versus-leukemia effect in acute myeloid leukemia patients, Blood, vol.118, issue.5, pp.1402-1412, 2011. ,
DOI : 10.1182/blood-2010-08-304121
Cytomegalovirus reactivation is associated with a lower rate of early relapse in myeloid malignancies independent of in-vivo T cell depletion strategy, Leukemia Research, vol.57 ,
DOI : 10.1016/j.leukres.2017.02.009
The graft-versus-leukemia effect is mainly restricted to NIH-defined chronic graft-versus-host disease after reduced intensity conditioning before allogeneic stem cell transplantation, Leukemia, vol.94, issue.11, pp.1852-1858, 2010. ,
DOI : 10.1200/JCO.2005.08.136
Impact of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European group for blood and marrow transplantation, Leukemia, vol.11, issue.12, pp.2462-2468, 2012. ,
DOI : 10.1056/NEJMoa1108188
Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation Graft-versus-host disease induced graft-versus-leukemia effect: greater impact on relapse and disease-free survival after reduced intensity conditioning, J Clin Oncol. Biol Blood Marrow Transplant, vol.3118, issue.7011, pp.1530-15381727, 2012. ,
Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia, Blood, vol.121, issue.12, pp.2213-2223, 2013. ,
DOI : 10.1182/blood-2012-10-462879
Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations, Leukemia, vol.106, issue.6, pp.1103-1108, 2006. ,
DOI : 10.1182/blood-2005-02-0560
Wilms??? tumor gene 1 expression: an independent acute leukemia prognostic indicator following allogeneic hematopoietic SCT, Bone Marrow Transplantation, vol.47, issue.4, pp.499-507, 2012. ,
DOI : 10.1111/j.1365-2141.2009.07770.x
URL : http://www.nature.com/bmt/journal/v47/n4/pdf/bmt2011121a.pdf
Pre-and post-transplant quantification of measurable ('minimal') residual disease via multiparameter flow cytometry in adult acute myeloid leukemia Prognostic impact of minimal residual disease analysis by flow cytometry in patients with acute myeloid leukemia before and after allogeneic hemopoietic stem cell transplantation, Leukemia. Bastos-Oreiro M Eur J Haematol, vol.3093, issue.753, pp.1456-1464239, 2014. ,
/ITD acute myeloid leukemia, Pediatric Blood & Cancer, vol.116, issue.6, pp.1048-1054, 2015. ,
DOI : 10.1016/j.bbmt.2011.07.011
Chimerism status is a useful predictor of relapse after allogeneic stem cell transplantation for acute leukemia, Haematologica, vol.88, issue.7, pp.801-810, 2003. ,
Preemptive immunotherapy in childhood acute myeloid leukemia for patients showing evidence of mixed chimerism after allogeneic stem cell transplantation, Blood, vol.118, issue.20, pp.5681-5688, 2011. ,
DOI : 10.1182/blood-2011-04-348805
Rezidivprophylaxe bei Kindern mit ALL-, AML- und MDS nach allogener Stammzelltransplantation durch interventionelle Immuntherapie im kritischen Stadium eines ansteigenden gemischten Chim??rismus, Klinische P??diatrie, vol.214, issue.4, pp.201-205, 2002. ,
DOI : 10.1055/s-2002-33176
Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation, Blood, vol.119, issue.6, pp.1599-1606, 2012. ,
DOI : 10.1182/blood-2011-08-375840
Outcomes of patients with AML and MDS who relapse or progress after reduced intensity allogeneic hematopoietic cell transplantation, Bone Marrow Transplantation, vol.12, issue.11, pp.1027-1032, 2007. ,
DOI : 10.1016/S0301-472X(03)00225-X
Relapse after allogeneic stem cell transplantation, Expert Review of Hematology, vol.16, issue.4, pp.429-441, 2010. ,
DOI : 10.1016/j.bbmt.2009.10.023
Outcome and Prognostic Factors for Patients Who Relapse after Allogeneic Hematopoietic Stem Cell Transplantation, Biology of Blood and Marrow Transplantation, vol.19, issue.12, pp.1713-1718, 2013. ,
DOI : 10.1016/j.bbmt.2013.09.011
Outcome of relapse after allogeneic stem cell transplant in patients with acute myeloid leukemia, Leukemia & Lymphoma, vol.93, issue.6, pp.1228-1234, 2013. ,
DOI : 10.1002/ajh.21478
Clinical outcomes of AML patients relapsing after matched-related donor and umbilical cord blood transplantation, Bone Marrow Transplantation, vol.361, issue.8, pp.1029-1035, 2014. ,
DOI : 10.1056/NEJMoa0811036
Efficacy of immune suppression tapering in treating relapse after reduced intensity allogeneic stem cell transplantation, Haematologica, vol.100, issue.9, pp.1222-1227, 2015. ,
DOI : 10.3324/haematol.2015.129650
Donor Lymphocyte Infusion in the Treatment of First Hematological Relapse After Allogeneic Stem-Cell Transplantation in Adults With Acute Myeloid Leukemia: A Retrospective Risk Factors Analysis and Comparison With Other Strategies by the EBMT Acute Leukemia Working Party, Journal of Clinical Oncology, vol.25, issue.31, pp.4938-4945, 2007. ,
DOI : 10.1200/JCO.2007.11.6053
Second allogeneic transplantation for relapse of malignant disease: retrospective analysis of outcome and predictive factors by the EBMT, Bone Marrow Transplantation, vol.19, issue.12, pp.1542-1550, 2015. ,
DOI : 10.1038/sj.bmt.1704761
Second Allograft for Hematologic Relapse of Acute Leukemia After First Allogeneic Stem-Cell Transplantation From Related and Unrelated Donors: The Role of Donor Change, Journal of Clinical Oncology, vol.31, issue.26, pp.313259-3271, 2013. ,
DOI : 10.1200/JCO.2012.44.7961
Outcome of second allogeneic transplants using reduced-intensity conditioning following relapse of haematological malignancy after an initial allogeneic transplant, Bone Marrow Transplantation, vol.74, issue.12, pp.783-789, 2008. ,
DOI : 10.1111/j.1423-0410.1998.tb05438.x
Haploidentical Stem Cell Transplantation for Acute Leukemia Patients Who Experienced Early Relapse Within One Year After the First Transplantation, Transplantation Proceedings, vol.46, issue.10, pp.3611-3615, 2014. ,
DOI : 10.1016/j.transproceed.2014.04.011
Second haematopoietic SCT using HLA-haploidentical donors in patients with relapse of acute leukaemia after a first allogeneic transplantation, Bone Marrow Transplantation, vol.9, issue.7, pp.895-901, 2014. ,
DOI : 10.1182/blood-2009-07-235358
Novel strategies to prevent relapse after allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia and myelodysplastic syndromes, Current Opinion in Hematology, vol.22, issue.2, pp.116-122, 2015. ,
DOI : 10.1097/MOH.0000000000000116
Relapse of AML after hematopoietic stem cell transplantation: methods of monitoring and preventive strategies. A review from the ALWP of the EBMT, Bone Marrow Transplantation, vol.134, issue.11, pp.1431-1438, 2016. ,
DOI : 10.1002/cncr.23375
Tolerability and Clinical Activity of Post-Transplantation Azacitidine in Patients Allografted for Acute Myeloid Leukemia Treated on the RICAZA Trial, Biology of Blood and Marrow Transplantation, vol.22, issue.2, pp.385-390, 2016. ,
DOI : 10.1016/j.bbmt.2015.09.004
Efficacy and feasibility of sorafenib as a maintenance agent after allogeneic hematopoietic stem cell transplantation for Fms-like tyrosine kinase 3-mutated acute myeloid leukemia, Cancer, vol.124, issue.15, pp.2867-2874, 2017. ,
DOI : 10.1182/blood-2014-05-578070
CLINICAL MANIFESTATIONS OF GRAFT-VERSUS-HOST DISEASE IN HUMAN RECIPIENTS OF MARROW FROM HL-A-MATCHED SIBLING DONOR,S, Transplantation, vol.18, issue.4, pp.295-304, 1974. ,
DOI : 10.1097/00007890-197410000-00001
Chronic graft-versus-host syndrome in man, The American Journal of Medicine, vol.69, issue.2, pp.204-217, 1980. ,
DOI : 10.1016/0002-9343(80)90380-0
Isolated Extramedullary Relapse of Acute Leukemia after Allogeneic Stem Cell Transplantation: Different Kinetics and Better Prognosis than Systemic Relapse, Biology of Blood and Marrow Transplantation, vol.23, issue.7, pp.1087-1094, 2017. ,
DOI : 10.1016/j.bbmt.2017.03.023
Impact of Cyclosporine-A Concentration on the Incidence of Severe Acute Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation, Biology of Blood and Marrow Transplantation, vol.16, issue.1, pp.28-34, 2010. ,
DOI : 10.1016/j.bbmt.2009.08.010
Assessment of cyclosporine serum concentrations on the incidence of acute graft versus host disease post hematopoietic stem cell transplantation, Iran J Pharm Res, vol.13, issue.1, pp.305-312, 2014. ,
GVHD prophylaxis using low-dose cyclosporine improves survival in leukaemic recipients of HLA-identical sibling transplants, European Journal of Haematology, vol.2, issue.4 ,
DOI : 10.3109/10428199609045715
High rate of hematological responses to sorafenib in FLT3-ITD acute myeloid leukemia relapsed after allogeneic hematopoietic stem cell transplantation, European Journal of Haematology, vol.20, issue.6, pp.629-636, 2016. ,
DOI : 10.1016/j.bbmt.2013.08.012
Allogeneic Hematopoietic Stem Cell Transplantation in FLT3 -ITD???Positive Acute Myelogenous Leukemia: The Role for FLT3 Tyrosine Kinase Inhibitors Post-Transplantation, Biology of Blood and Marrow Transplantation, vol.22, issue.6, pp.982-990, 2016. ,
DOI : 10.1016/j.bbmt.2016.01.013
Clinically relevant doses of FLT3-kinase inhibitors quizartinib and midostaurin do not impair T-cell reactivity and function, Haematologica, vol.99, issue.6, pp.90-93, 2014. ,
DOI : 10.3324/haematol.2014.104331
Phase I Trial of Maintenance Sorafenib after Allogeneic Hematopoietic Stem Cell Transplantation for Fms-like Tyrosine Kinase 3 Internal Tandem Duplication Acute Myeloid Leukemia, Biology of Blood and Marrow Transplantation, vol.20, issue.12, pp.2042-2048, 2014. ,
DOI : 10.1016/j.bbmt.2014.09.007